key: cord-0830341-3dkluuch
authors: Constans, Mireia; Santiago, Raquel; Jimenez, Lidia; Motllo, Cristina; Lopez, Rosario; Trapé, Jaume; Reverter, J. Carlos; Altes, Albert
title: Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients
date: 2021-10-23
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.10.017
sha: d144e2359079fd060295bfbcc2a80de13f9a5c77
doc_id: 830341
cord_uid: 3dkluuch

BACKGROUND: Thromboembolic disease is a frequent cause of death during SARS CoV-2 infection. Lupus anticoagulant (LA) appears frequently during the acute phase of infection. It is not clear whether it is merely an epiphenomenon or whether it is related to the patients' outcome. METHODS: Prospective observational cohort of 211 patients (118 women, mean age 65 years, range: 18 to 99) hospitalized for COVID-19. All patients were tested for LA at admission and retested six months after discharge. RESULTS: The LA test was positive in 128 patients (60.7%). The survival probability at 31 days was clearly worse in the LA-positive group (60%) than in the LA-negative group (90%) (P = 0.023). This notable difference in survival was confirmed by multivariate analysis (HR 3.9, 95% CI 1.04–14.5, P = 0.04). However, it was not explained by differences in thrombotic events (three in either group, P = 0.6). LA-positive patients had higher ferritin, CRP and IL-6 levels, and lower PAFI ratio and lymphocyte and platelet counts. Six months after discharge, LA was negative in the vast majority of positive cases (94%). CONCLUSION: LA is an independent predictor of in-hospital mortality in COVID-19 patients. It is associated with inflammation and disease severity but not with thromboembolic events. This marker usually disappears at six months.

anticoagulant (LA) in patients with a history of thrombosis or pregnancy complications was defined for the diagnosis of antiphospholipid syndrome (APS) according to the international criteria of rheumatology [6] . Both types of antibodies are directed at antiphospholipid of the endothelium and platelets and LA can affect in vitro blood coagulation tests. LA is detected using functional assays that demonstrate a PL-dependent prolongation of the clotting time, due to the in vitro interference of antibodies with PL-dependent function. The ISTH established the following criteria to confirm the presence of LA: Phospholipid dependent prolonged coagulation tests, dRVVT should be the first test considered, demonstration of the coagulation inhibitor utilizing mixed plasma, demonstration of the PL dependence of the inhibitor and ruling out other coagulation disorders, particularly due to deficiency of coagulation factors [7] . LA may appear in acute infections without an increased thrombotic risk, and this is considered an autoimmune epiphenomenon [8, 9] . Initial reports suggested that APA and LA may be relevant in this context. Three patients diagnosed with COVID-19 pneumonia admitted to an intensive care unit (ICU) had severe thrombosis in multiple locations associated with APA [10] . Nevertheless, in a series of 24 COVID-19 patients with serious thrombosis, only two had APA in serum [11] . In another series of 31 consecutive confirmed COVID-19 patients admitted to the ICU, 52% presented LA and 22% APA [12] .

LA was very frequent in three series of patients with COVID-19 pneumonia, but no pathological association with thrombosis was found [12] [13] [14] . However, LA was detected in 87% of ICU patients that suffered thrombosis or had an abnormal activated partial thromboplastin time (APTT) [15] .

prevalence of LA at diagnosis and six months after discharge, in order to estimate its impact on mortality and thrombosis in a prospective observational cohort of COVID-19 patients.

We included 211 consecutively admitted adults with COVID-19 attended between April 7-20, 2020 at the emergency service of the Hospital de Sant Joan de Déu, Manresa (Barcelona), Spain. Inclusion criteria were age > 18 years and fulfillment of the clinical, radiological and laboratory characteristics of COVID-19 infection, with a diagnosis of SARS CoV-2 on RT-PCR. Patients consulting a second time for the same disease, were excluded, as were those treated with anticoagulant drugs. The study was performed in accordance with the Declaration of Helsinki. Oral informed consent was obtained from all patients prior to participation. Six months after discharge, all patients < 80 years old were invited to undergo tests to detect the presence of LA in their plasma. Written informed consent was obtained from all participants and the study was approved by the Institutional Ethics Committee.

A nasopharyngeal sample was obtained for the RT-PCR test for SARS CoV-2 from all patients at admission, and was repeated if the result was negative. RNA SARS CoV2 was detected by Reverse Transcription (RT)-polymerase chain reaction (PCR) using Thermofisher Quantstudio 5q, measuring three viral genes: ORF1, S and N. The day of symptom onset and clinical data were obtained from the medical record (sex, age, smoking status, obesity, high blood pressure (HBP), diabetes, hyperlipidemia, history of thrombosis, active neoplasia and antiplatelet drugs). Patients were classified as obese when this term appeared in the medical record but no score was used. The sepsis-induced coagulopathy (SIC) score (<4 or ≥4) was calculated according to the Sequential Organ Failure (SOFA) score, number of platelets and PT-INR, as described elsewhere [17] . PaO2/FiO2 (PAFI) at J o u r n a l P r e -p r o o f Journal Pre-proof admission was also recorded.

Blood samples (3 ml EDTA tube, 2.7 ml 0.129 M coagulation citrate tube, 5 ml biochemical serum tube, and 6 ml lithium heparin tube) were obtained during admission before initiating treatment and were processed immediately. 

Administration of lopinavir/ritonavir, hydroxychloroquine, azithromycin (KDA), tocilizumab and corticosteroids during admission was recorded. Patients were followed during hospitalization to detect arterial or venous thromboembolic disease, acrocyanosis, and the need for mechanical ventilation. Vital status was recorded at discharge.

Continuous variables are presented as means and standard deviations or medians and interquartile ranges (when appropriate), and categorical variables are presented as counts and frequencies. Differences between categorical variables were analyzed using the Chi-square test, and differences between means in continuous variables by the Student's T test for 

We included 211 patients, 118 (60%) females, mean age 65 years (range: 18 to 99 years).

One patient had active cancer. Table 1 summarizes clinical and laboratory data at hospital admission. The median duration of symptoms before admission was eight days and the median hospital stay was also eight days. The LA test was positive in 128 patients (60.7%).

APA were randomly tested in 30 patients (six with thrombosis); only one (without thrombosis) tested positive (3.33%, anti-beta-2-glycoprotein Ig G).

Clinical and laboratory data according to LA status are shown in Table 1 Seven thromboembolic events were recorded in six patients: two pulmonary embolisms (PE), two ischemic strokes (IS) and three acute myocardial infarctions (AMI). The clinical characteristics of these patients are shown in Table 2 . No significant between-group differences in thrombotic events were found (P=0.6).

In the Cox regression model LA positive was an independent predictor of mortality during hospitalization, after adjustment for other clinical and analytical variables (age, sex, smoker, obesity, HBP, dyslipidemia, diabetes, history of thrombosis, antiplatelet treatment, SIC score, PaO2/FiO2, platelet and lymphocyte counts, NL transformation of ferritin, DD, LDH, IL-6 and CRP levels): HR=3.9 (95% CI: 1.04 -14.5) ( Table 3) . Other variables associated with survival were age, history of thrombosis and IL-6 levels. 

It seems that LA is frequently present in critical COVID-19 patients [5, 10, 12, 19, 20] , but its prevalence at diagnosis and its relationship with thrombosis and mortality have received less attention.

LA is known to appear in some acute infections and is normally considered an autoimmune epiphenomenon without clinical consequences [9] . We studied whether its appearance in the context of SARS-CoV-2 is one such case or, in contrast, is associated with mortality and thromboembolic morbidity. LA measurement may be distorted by the presence of anticoagulants in the blood sample, leading to an increase in false positive results. In contrast to other studies [5, 10, 12, 13, 19] , samples in our patients were obtained at admission and before starting any treatment, an ideal situation for assessing the LA status without interference.

We found a very high prevalence of LA (60.7%) at COVID-19 diagnosis, higher than that found in other viral infections [9] . Only 3% of 30 random patients had APA, lower than in other series [11, 12, 20, 21] , so we decided not to test all patients. LA was especially frequent in men and in obese patients. Patients with LA sought medical care more rapidly (with shorter times since symptom onset), suggesting that the disease was more aggressive or symptomatic. These patients had, in general, poorer clinical and biologic parameters (lower PAFI, platelets and lymphocytes and higher ferritin, LDH, CRP and IL6 levels), suggesting a wide range of inflammation and, in general, a poorer prognosis. Hospital stay was also significantly longer in LA-positive patients.

The APTT ratio was within normal laboratory reference ranges in all patients except one, J o u r n a l P r e -p r o o f Journal Pre-proof who had a slight increase. There were significant differences in the APTT ratio according to the LA result, but without any clinical significance. This contrasts with the findings of Bowles et al. [13] who reported that of 44 out of 216 patients with prolonged APTT (20%) 91% were LA-positive, although the authors noted that heparin was detected in 80% of the samples. An analysis performed under similar heparin-free conditions [16] described the same presence of LA without increased APTT. We observed an elevated PT ratio in 12 patients (5%) without differences according to LA positivity.

The decision to use several drugs to treat patients (KDA, tocilizumab and corticosteroids) was based on symptom severity, respiratory status and inflammatory parameters. The LApositive patients were treated more intensively with KDA and tocilizumab, but there were no differences with regard to corticosteroid treatment.

In agreement with other reports [12, 13, 14, 16] , we found no differences in the rate of thrombotic events between the two groups We only observed significant differences between levels of the natural logarithm transformation of the DD level, which was higher in patients with subsequent thrombosis, also in agreement with previous studies [22] .

The main outcome of this study is that LA is closely associated with mortality during hospitalization. The hazard ratio of hospital death in LA-positive patients was 3.9. To our knowledge, this is the first study to assess LA as a prognostic factor in COVID-19 patients and to report a strong association with in-hospital mortality. Interestingly, this association was independent of thromboembolic events. study, 24% of patients in the positive LA group died compared with 15% in the negative group; this difference is in agreement with our results, but did not reach statistical significance (P=0.42). A factor closely associated with inflammatory parameters would be expected to be related to a poor prognosis and death, as we observed in our study.

The thromboembolic events observed in this series were not related to LA status and their frequency (six patients, 2.84%), was significantly lower than in other studies [5, 15, 23] . This is probably due to the more critical condition of patients in the other series. All our patients were treated according to the recommendations published by the ISTH in March 2020 [4] which increased the dose of low-molecular-weight heparin in all patients in general, and especially in patients with high levels of biomarkers of thrombosis.

It might be hypothesized that LA appears in the context of an intense inflammation that causes severe endothelial damage, microvascular injury, and organ dysfunction related to disease severity. Our study lends supported to this theory due to the intense relationship observed between LA and a high number of variables directly related with inflammatory status, and also due to the fact that 94% of patients with positive LA during the inflammatory phase of the disease became negative at six months. Some reports have speculated on a possible relationship between LA as a bridge to other cofactors like complement and cytokine activation, which are responsible for vascular damage [12] . Many assays for detecting LA are sensitive to CRP; this interferes with the results and results in false positives [21] . CRP is an acute phase protein with known affinity for APA [24, 25, 26] . In our study, although CRP levels were higher in LA-positive patients (p <0.001) this variable did not emerge as a prognostic factor of mortality in the multivariate model.

Other variables associated with survival in the multivariate model were age, a history of thrombosis, and lymphocyte count. Age and lymphocyte count are known to be related to survival in COVID-19 [22, 27] . Moreover, a history of thrombosis was also found to be an J o u r n a l P r e -p r o o f Journal Pre-proof intense and independent risk factor for death in COVID-19 patients (HR 5.5). In contrast, Ferrari et al. [20] found that thrombophilia was not linked to mortality and was not a prognostic risk factor per se, although they did not present the underlying clinical data.

Our study has some limitations. First, data were collected indirectly from the emergency medical record, and follow-up was limited to the period of hospitalization. Second, obesity was not classified systematically by body mass index. Third, we did not diagnose subclinical thrombosis in asymptomatic patients, as this was impossible during the pandemic. Fourth, the fact that we did not use a second silica LA test may have reduced the sensitivity of detection.

Finally, only 70 patients participated in the follow-up six months after discharge. We excluded patients older than 80 years for safety reasons, and 69 declined to participate. All these drawbacks are to be expected during a pandemic without an accessible vaccine.

In summary, LA positivity in COVID-19 is highly prevalent and closely associated with inhospital mortality and inflammation markers, but not with thromboembolic events. Our study suggests that more intense anti-inflammatory treatment should be started in patients with a positive LA test at diagnosis. Determining the presence of LA could be useful for stratifying the risk of death in COVID-19 patients. The relationship between the appearance of LA and inflammation should be studied in depth because it may indicate the presence of a new pathophysiological pathway in this disease. 

World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

J o u r n a l P r e -p r o o f Journal Pre-proof international consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Update of the guidelines for lupus anticoagulant detection

EULAR recommendations for the management of antiphospholipid syndrome in adults

Viral infections and antiphospholipid antibodies

Coagulopathy and COVID-19 pneumonia and venous thromboembolism

Antiphospholipid antibodies in patients with COVID-19: A relevant observation?

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Coagulation abnormalities and thrombosis in patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

COVID-19 and its implications for thrombosis and anticoagulation

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease

Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study

Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis

Coagulopathy of COVID-19 and antiphospholipid antibodies

COVID-19)

Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?

Critically Ill Patients in the Seattle Region -Case Series

We thank Dr. Roberto Elosua for his advice on the publication.

Universitària de Manresa.

Hospital stay--days 8